Alpha Diallo
0
All posts from Alpha Diallo
Alpha Diallo in Alpha Diallo,

Halozyme Therapeutics advancing on meeting a target for an experimental cellulite drug

 (Image source: xconomy.com)

Shares of the biopharmaceutical company Halozyme Therapeutics, Inc. (NASDAQ:HALO) are rallying in early trading as a result of a clinical trial for cellulite meeting the company’s expectations. The experimental cellulite drug (HTI-501) during phase I testing showed signs of decreasing cellulite on patients.  Millions of women suffer from cellulite.